Press Releases
Naveris Announces Expansion of the NavDx® Test in Anal Cancer Molecular Residual Disease Surveillance
The NavDx test demonstrates high performance in detecting recurrent disease, providing an enhanced and widely accessible surveillance tool for HPV+ anal squamous cell carcinoma patients WALTHAM, Mass. Naveris, Inc., the…
Read More
Naveris Announces Expanded Commercial Payor Coverage for NavDx Test from Blue Shield of California
Coverage from Blue Cross Blue Shield Association Licensee Increases Patient Access to Precision Medicine WALTHAM, Mass. - Naveris, Inc., the leader in precision oncology diagnostics for viral-induced cancers, today announced…
Read More
Naveris to Showcase Advances in Precision Surveillance for HPV-Associated Oropharyngeal Cancer Using the NavDx® Test at the 2024 ASTRO Annual Meeting
WALTHAM, Mass. - Naveris, Inc., the leader in precision oncology diagnostics for viral-induced cancers, today announced the presentation of new data at the 66th Annual Meeting of the American Society for…
Read More
Naveris Presents New Data on the NavDx® test for HPV-Associated Oropharyngeal Cancer at the 2024 AAO-HNS Annual Meeting
WALTHAM, Mass. - Naveris, Inc., the leader in precision oncology diagnostics for viral-induced cancers, today announced the presentation of new data at the 2024 Annual Meeting of the American Academy…
Read More
New Multicenter Study Highlights Use of the NavDx® Test in Resolving Clinically Indeterminate Findings
Data Adds to Substantial Body of Evidence Demonstrating NavDx's Important Role in Oropharyngeal Cancer Surveillance WALTHAM, Mass. (June 27, 2024) – Naveris, Inc., the leader in precision oncology diagnostics…
Read More
Naveris to Present New Data Highlighting Clinical Utility of the NavDx® Test at the 2024 ASCO Annual Meeting
WALTHAM, Mass. (May 29, 2024) – Naveris, Inc., the leader in precision oncology diagnostics for viral-induced cancers, today announced new data to be presented at The American Society of Clinical…
Read More
Naveris Announces Launch of Phase II Clinical Study in MRD+ Head and Neck Cancer
NavDx to be used to identify eligible patients with molecular relapse after definitive treatment for HPV16+ head and neck squamous cell cancer and to monitor throughout study WALTHAM, Mass.…
Read More
Naveris Awarded ADLT Status by CMS for the NavDx® Test
WALTHAM, Mass. (March 21, 2024)– Naveris, Inc., the leader in precision oncology diagnostics for viral-related cancers, today announced that the Centers for Medicare & Medicaid Services (CMS) has granted Advanced…
Read More
Naveris Announces New Data at EUROGIN International Multidisciplinary HPV Congress 2024
Data presented showcases clinical utility of NavDx for patients with HPV-driven anal cancer WALTHAM, Mass. (March 14, 2024)– Naveris, Inc., the leader in precision oncology diagnostics for viral-induced cancers, announced…
Read More
Naveris Unveils NAVigate-HPV: A Groundbreaking Registry to Advance HPV-Driven Cancer Diagnosis and Treatment
Naveris Unveils NAVigate-HPV: A Groundbreaking Registry to Advance HPV-Driven Cancer Diagnosis and Treatment Initiative will bring together largest ever research consortium to generate definitive biomarker data repository for HPV-driven cancers…
Read More
Naveris Announces New Data at ASTRO Multidisciplinary Head and Neck Cancers Symposium 2024
Naveris Announces New Data at ASTRO Multidisciplinary Head and Neck Cancers Symposium 2024 WALTHAM, Mass. (February 28, 2024)– Naveris, Inc., the leader in precision oncology diagnostics for viral-induced cancers,…
Read More
Naveris Announces Commercial Payor Coverage for NavDx® Test from Highmark, Inc.
Naveris Announces Commercial Payor Coverage for NavDx® Test from Highmark, Inc. Commercial Coverage from Blue Cross Blue Shield Association Licensee Adds to Growing Coverage from Medicare and Other Carriers …
Read More
Naveris Receives Medicare Coverage for NavDx® Test
Proprietary blood test now covered for all Medicare beneficiaries with HPV-driven head and neck cancer WALTHAM, Mass. (November 30, 2023) – Naveris, Inc., the leader in precision oncology diagnostics…
Read More
Naveris Announces Two Peer-Review Publications Validating NavDx® Performance in Daily Clinical Practice
Waltham, MA., October 12, 2023 --(BUSINESS WIRE)-- Naveris, Inc., the leader in precision oncology diagnostics for viral-induced cancers, today announced the publication of two new peer-review studies in the journals Clinical…
Read More
Naveris Announces New Data Featuring NavDx® in Oral Highlight and Poster Presentations at Upcoming ASTRO and AAO-HNSF 2023 Meetings
Waltham, MA., September 28, 2023 --(BUSINESS WIRE)-- Naveris, Inc. , the leader in precision oncology diagnostics for viral-induced cancers, today announced that the company will be attending The American Academy of…
Read More
Mayo Clinic Collaborates with Naveris to Advance Precision Medicine in HPV-driven Head and Neck Cancer with NavDx in DART 2.0 Clinical Trial
Waltham, MA., April 12, 2023 --(BUSINESS WIRE)-- Naveris, Inc., a leader in molecular diagnostics for viral cancers, today announced the launch of the DART 2.0 prospective clinical trial (NCT05541016) by…
Read More
Naveris Collaborators Present Award-winning Abstract at ASTRO 2022 on Potential of NavDx to Inform Treatment Strategies in HPV-driven Cancers
Natick, MA., October 24, 2022 --(BUSINESS WIRE)-- Naveris, Inc., a leader in molecular diagnostics for viral cancers, today announced that the company and the principle investigator at Mayo Clinic will…
Read More
Naveris, Inc. Raises $51 Million to Advance Commercialization of NavDx
Natick, MA., September 19, 2022 --(BUSINESS WIRE)-- Naveris, Inc., a commercial-stage life sciences company dedicated to improving patient care through earlier detection of viral-driven cancers, today announced a $33.4 million…
Read More
Naveris Announces Abstract Accepted for Presentation at the 2022 American Society for Clinical Oncology (ASCO) Annual Meeting
Natick, MA., June 3, 2022 --(BUSINESS WIRE)-- Naveris, Inc. announces the presentation of an abstract related to its flagship diagnostic test for TTMV-HPV DNA (NavDx®) at the 2022 American Society…
Read More
Naveris’ Head and Neck Cancer Recurrence Detection Study Selected for Presentation at ASTRO 2022 Plenary Session
Natick, MA., February 24, 2022 --(BUSINESS WIRE)-- Naveris, Inc., a leader in molecular diagnostics for viral cancers, today announced the presentation of significant new data at the plenary session of the…
Read More
New Saliva Test Detects Head and Neck Cancer
Waltham, MA., June 2, 2021 --(BUSINESS WIRE)-- A new clinically-validated saliva test has been shown to detect HPV-associated head and neck cancer with high accuracy, a first-of-its-kind study result. …
Read More
Naveris, Inc. Raises $19 Million in Financing to Advance and Commercialize Blood Tests for Early Detection of HPV and Other Viral-Related Cancers
Waltham, MA., December 15, 2020 --(BUSINESS WIRE)-- Naveris, a healthcare company dedicated to improving patient care through early detection of virus-related cancers, today announced the close of its expanded Series…
Read More
Blood Test Accurately Identifies HPV-related Head and Neck Cancer Recurrence; Prospective Clinical Study Published in Journal of Clinical Oncology
Waltham, MA., February 5, 2020 --(BUSINESS WIRE)-- A novel blood test can detect recurrent Human Papilloma Virus (HPV)-related head and neck (oropharyngeal) cancers, according to a study published online in…
Read More
Naveris Congratulates Scientific Advisors Bhisham Chera and Gaorav Gupta on Presentation of Clinical Data at the 2018 ASTRO Annual Meeting
WALTHAM, Mass., Oct. 22, 2018 /PRNewswire/ -- Naveris, Inc., a private biotechnology company developing blood tests for early cancer detection, congratulates Bhisham Chera, M.D. and Gaorav Gupta, M.D., Ph.D., scientific…
Read More